---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-174958"
form_type: "8-K"
ticker: "SLN"
cik: "0001479615"
company_name: "Silence Therapeutics plc"
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:25:48.866540+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Silence Therapeutics Q2 net loss widens to $27.4M; cash $114.2M, divesiran Phase 2 on track

## Summary
- Net loss of $27.4M in Q2 2025 vs $19.8M in Q2 2024; R&D expenses rose to $17.6M.
- Cash and short-term investments $114.2M as of June 30, 2025; expected to fund operations into 2028.
- Divesiran Phase 2 SANRECO trial >50% enrolled; on track for full enrollment by year-end 2025.
- Paused Phase 1 initiation of SLN548 to prioritize extra-hepatic siRNA targeting; preclinical data promising.
- Zerlasiran Phase 3 readiness activities completed; seeking partnership for Phase 3 and commercialization.

## SEC filing metadata
- accession: 0001193125-25-174958
- form_type: 8-K
- ticker: SLN
- cik: 0001479615
- company_name: Silence Therapeutics plc
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479615/000119312525174958/0001193125-25-174958-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479615/000119312525174958/d14149d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-174958
- JSON: https://secwatch.observer/filing/0001193125-25-174958.json
- Plain text: https://secwatch.observer/filing/0001193125-25-174958.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.